Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines

View ORCID ProfileVivek Naranbhai, Wilfredo F. Garcia-Beltran, Christina C. Chang, Cristhian Berrios Mairena, Julia C. Thierauf, Grace Kirkpatrick, Maristela L. Onozato, Ju Cheng, Kerri J. St. Denis, Evan C. Lam, Clarety Kaseke, Rhoda Tano-Menka, Diane Yang, Maia Pavlovic, Wendy Yang, Alexander Kui, Tyler E. Miller, Michael G. Astudillo, Jennifer E. Cahill, Anand S. Dighe, David J. Gregory, Mark C. Poznansky, Gaurav D. Gaiha, Alejandro B. Balazs, A. John Iafrate
doi: https://doi.org/10.1101/2021.07.18.21260732
Vivek Naranbhai
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
2Dana-Farber Cancer Institute, Boston, MA USA
3Center for the AIDS Programme of Research in South Africa, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vivek Naranbhai
Wilfredo F. Garcia-Beltran
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina C. Chang
3Center for the AIDS Programme of Research in South Africa, Durban, South Africa
4University of New South Wales, Sydney, Australia
5Monash University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristhian Berrios Mairena
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia C. Thierauf
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Kirkpatrick
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maristela L. Onozato
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ju Cheng
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerri J. St. Denis
6Ragon Institute, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan C. Lam
6Ragon Institute, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clarety Kaseke
6Ragon Institute, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rhoda Tano-Menka
6Ragon Institute, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane Yang
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maia Pavlovic
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Yang
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Kui
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tyler E. Miller
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael G. Astudillo
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer E. Cahill
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anand S. Dighe
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Gregory
7Massachusetts General Hospital, Vaccine and Immunotherapy Center, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark C. Poznansky
7Massachusetts General Hospital, Vaccine and Immunotherapy Center, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaurav D. Gaiha
6Ragon Institute, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro B. Balazs
6Ragon Institute, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. John Iafrate
1Massachusetts General Hospital, Department of Pathology, Boston, MA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aiafrate@partners.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Understanding immunogenicity and effectiveness of SARS-CoV-2 vaccines is critical to guide rational use.

Methods We compared the immunogenicity of mRNA-1273, BNT-162b2 or Ad26.COV2.S in ambulatory adults in Massachusetts, USA. To correlate immunogenicity with effectiveness of the three vaccines, we performed an inverse-variance meta-analysis of population level effectiveness from public health reports in >40 million individuals.

Results A single dose of either mRNA vaccine yielded comparable antibody and neutralization titers to convalescent individuals. Ad26.COV2.S yielded lower antibody concentrations and frequently negative neutralization titers. Bulk and cytotoxic T-cell responses were higher in mRNA1273 and BNT162b2 than Ad26.COV2.S recipients, and <50% of vaccinees demonstrate CD8+ T-cell responses to spike peptides. Antibody concentrations and neutralization titers increased comparably after the first dose of either vaccine, and further in recipients of a second dose. Prior infection was associated with high antibody concentrations and neutralization even after a single dose and regardless of vaccine. Neutralization of beta, gamma and delta strains were poorer regardless of vaccine. Relative to mRNA1273, the effectiveness of BNT162b2 was lower against infection and hospitalization; and Ad26COV2.S was lower against infection, hospitalization and death.

Conclusions Variation in the immunogenicity correlates with variable effectiveness of the three FDA EUA vaccines deployed in the USA.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

D.J.G., M.C.P., and M.N.P. were supported by the VIC Innovation fund. A.J.I. and this study were supported by the Lambertus Family Foundation. G.D.G. is supported by a Burroughs Wellcome Career Award in Medical Sciences. A.B.B. was supported by the National Institutes for Drug Abuse (NIDA) Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars Program as well as funding from the Charles H. Hood Foundation

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Use of human samples was approved by Partners Institutional Review Board (protocol 2020P001081 and 2020P002274).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • 1. Includes meta-analysis of public health reports regarding vaccine effectiveness (Figure 5) 2. Includes comparative neutralization of SARS CoV-2 viral variants (Figure 4) 3. Includes CD4 and CD8+ T-cell responses to SARAS CoV-2 Spike peptides (Figure 2)

Data Availability

Primary data is not available per the limited consent obtained from patients. Summary data are available by writing to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines
Vivek Naranbhai, Wilfredo F. Garcia-Beltran, Christina C. Chang, Cristhian Berrios Mairena, Julia C. Thierauf, Grace Kirkpatrick, Maristela L. Onozato, Ju Cheng, Kerri J. St. Denis, Evan C. Lam, Clarety Kaseke, Rhoda Tano-Menka, Diane Yang, Maia Pavlovic, Wendy Yang, Alexander Kui, Tyler E. Miller, Michael G. Astudillo, Jennifer E. Cahill, Anand S. Dighe, David J. Gregory, Mark C. Poznansky, Gaurav D. Gaiha, Alejandro B. Balazs, A. John Iafrate
medRxiv 2021.07.18.21260732; doi: https://doi.org/10.1101/2021.07.18.21260732
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines
Vivek Naranbhai, Wilfredo F. Garcia-Beltran, Christina C. Chang, Cristhian Berrios Mairena, Julia C. Thierauf, Grace Kirkpatrick, Maristela L. Onozato, Ju Cheng, Kerri J. St. Denis, Evan C. Lam, Clarety Kaseke, Rhoda Tano-Menka, Diane Yang, Maia Pavlovic, Wendy Yang, Alexander Kui, Tyler E. Miller, Michael G. Astudillo, Jennifer E. Cahill, Anand S. Dighe, David J. Gregory, Mark C. Poznansky, Gaurav D. Gaiha, Alejandro B. Balazs, A. John Iafrate
medRxiv 2021.07.18.21260732; doi: https://doi.org/10.1101/2021.07.18.21260732

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1095)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9766)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1557)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11638)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2141)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1175)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4654)
  • Radiology and Imaging (776)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)